On A Roll: Gilead's Top-Line Quad Data Stack Up To Atripla
This article was originally published in The Pink Sheet Daily
After announcing FDA approval of a new HIV combination last week, Gilead released positive comparative data on the Quad pill Aug. 15.
You may also be interested in...
Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.